ANDA 208837, held by Dr Reddys. Levothyroxine Sodium.
As of Nov 15, 2026, ANDA 208837 (Levothyroxine Sodium), held by Dr Reddys, was first approved by FDA on Mar 27, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levothyroxine Sodium100MCG/VIAL ยท powder;intravenous | Levothyroxine Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
